Patent · US Active

Antibody directed against the endothelin receptor beta sub-type

US11312780B2 · kind B2 · utility

0Cited by

1References

21Claims

0Family size

Assignee

COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR

Inventors

Didier Boquet · Les Pavillons-sous-Bois, FR
Frederic Ducancel · Longjumeau, FR
Amaury Herbet · Courbevoie, FR
Narciso Costa · Longjumeau, FR
Jean-Philippe Hugnot · Montpellier, FR

Key dates

Filing date	Jun 22, 2017
Grant date	Apr 26, 2022
Priority date	—
Expiry date	Jun 22, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies directed against the endothelin receptor sub-type B, in particular monoclonal antibodies, a fragment or derivative thereof. The present disclosure also relates to the therapeutic, diagnostic use or as a research tool of such an antibody in the field of cancers and in particular glioblastoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.